Clinical Trial

Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated December 19, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate a novel transplant strategy for the long-term benefit of patients with transfusion dependent high-risk thalassemia.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-06-15; most recent amendment 2023-12-13.
Trial Details
NCT Number NCT05426252
Lead Sponsor The Hospital for Sick Children
Collaborators: Thalassemia Foundation of Canada
Conditions Thalassemia in Children
Enrollment 20 participants
Start Date 2022-03-22
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-12-19